Coverage
-
August 17, 2020
A Texas federal judge said Friday that it would be futile for investors who'd already "pleaded their best case" to amend claims that Lexicon Pharmaceuticals overpromised on its ability to bring a new diabetes drug to market.
1 other articles on this case.
View all »